BioKangtai and AstraZeneca Announce Strategic Partnership to Advance Global Vaccine Innovation

BioKangtai has entered into a strategic partnership with AstraZeneca to establish a joint venture in the Beijing Economic-Technological Development Area. The venture will focus on researching, developing, and producing innovative vaccines.

This collaboration marks a significant milestone in BioKangtai’s mission to enhance global health and expand access to high-quality vaccines. The joint venture will serve as AstraZeneca’s first and only vaccine production hub in China, with a registered capital of RMB 345 million (approx. USD 50 million) and a total investment of approx. USD 400 million (RMB 2.76 billion). BioKangtai and AstraZeneca will each hold 50% equity in the venture. 

Through this partnership, BioKangtai and AstraZeneca aim to leverage their combined expertise to drive innovation and deliver vaccines tailored for both the Chinese market and emerging markets worldwide. This initiative not only strengthens BioKangtai’s global competitiveness but also positions the company to create meaningful value for public health. 

BioKangtai looks forward to working with AstraZeneca and other global partners to bring more innovative vaccine solutions to communities around the world. Together, they are committed to advancing health equity and improving lives. 

Learn more about this collaboration: (https://mp.weixin.qq.com/s/3f1CxPKwJi_mVlIe_oYTKw ).